Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
You may not be if
Type 1 Diabetes
History of gastroparesis or paralytic ileus
At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
Previous bariatric surgery
Medical condition likely to limit survival to less than 1 year
Anticipated start of dialysis or kidney transplantation within 6 months
Any factors judged by the investigator or study team to likely limit adherence to interventions
Vulnerable populations- pregnant or incarcerated
Enrolled in interventional trials using drugs or devices
Not able to undergo informed consent
Recent hospitalizations or major interventional procedures done within the past 60 days
Known or suspected hypersensitivity to tegaderm
Use of any GLP-1 receptor agonist within 30 days prior to screening
Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
Presence of metastatic cancer
Current use of mobility aid(s)
Living in the same household of a participant already enrolled in the study
